RUA Life Sciences plc
RUA.L · LSE
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | £0 | £0 | £0 | £0 |
| - Cash | £0 | £0 | £0 | £0 |
| + Debt | £0 | £0 | £0 | £0 |
| Enterprise Value | £0 | -£0 | £0 | £0 |
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | 87.7% | 0.6% | 34.1% | – |
| Gross Profit | £0 | £0 | £0 | £0 |
| % Margin | 77.1% | 78.3% | 65.8% | 64.3% |
| EBITDA | £0 | -£0 | -£0 | -£0 |
| % Margin | 9.7% | -71.8% | -89.4% | -125.5% |
| Net Income | £0 | -£0 | -£0 | -£0 |
| % Margin | 0% | -65.7% | -91.9% | -127.2% |
| EPS Diluted | 0 | -0.043 | -0.09 | -0.093 |
| % Growth | 100% | 52.5% | 3.1% | – |
| Operating Cash Flow | -£0 | -£0 | -£0 | -£0 |
| Capital Expenditures | -£0 | -£0 | -£0 | -£0 |
| Free Cash Flow | -£0 | -£0 | -£0 | -£0 |